Using a closed-loop system to manage diabetes in kidney transplant patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of a hybrid closed-loop system combined with a regular insulin pump and continuous glucose monitoring (CGM) for managing blood glucose levels in hospitalized patients with diabetes after kidney transplantation. The study aims to provide personalized blood glucose management plans and fill the existing gap in research focused on this specific patient population. By comparing the short-term blood glucose control effects of the closed-loop system against traditional methods, the trial seeks to explore the clinical application value of this advanced technology in diabetes treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 - 70 years;
* Meets the diagnostic criteria in the "Guidelines for Prevention and Control of Diabetes in China (2024 Edition)": A patient can be diagnosed with diabetes if he/she presents typical symptoms of diabetes (including polydipsia, polyuria, polyphagia, and unexplained weight loss) and meets one of the four criteria: ① random blood glucose ≥ 11.1 mmol/L; ② fasting blood glucose ≥ 7.0 mmol/L; ③ 2 - hour post - load blood glucose during an oral glucose tolerance test ≥ 11.1 mmol/L. For patients without typical symptoms, the diagnosis requires two abnormal test results obtained either simultaneously or at two different time points.
* Able to correctly use insulin pumps and CGM devices, and has certain learning and operational abilities;
* Agrees to participate in the study and signs the informed consent form.

Exclusion Criteria:

* The patient has experienced acute diabetic complications within the past month, such as diabetic ketoacidosis, hyperglycemic hyperosmolar coma, etc.
* The patient has severe symptoms of hypoglycemic intolerance.
* The patient has skin diseases such as rashes and prurigo, or abnormal coagulation function.
* The patient has diseases related to glucose metabolism, such as uncontrolled hyperthyroidism, uncontrolled hypothyroidism, Cushing's syndrome, etc.
* The patient has severe diseases of the liver, kidneys, gastrointestinal tract, hematopoietic system, brain, circulatory system, etc.
* Patients with malignant tumors (including solid tumors and hematological malignancies).
* The patient has impaired consciousness or mental illness, lacks self-control, and is unable to express clearly.
* Lactating women, pregnant women, or women who plan to become pregnant during the trial period.
* The patient is allergic to the drugs involved in the clinical diagnosis and treatment plan.
* The patient is currently using other closed-loop systems.
* Populations not suitable for conventional insulin pump therapy and contraindications.
* The patient has known or suspected insulin allergy, or is allergic to adhesive tape, insulin pumps, or CGM devices.
* Other situations where the investigator deems the patient unfit to participate in the clinical trial.

Where it's running

• Shanxi Bethune Hospital
  Taiyuan, Shanxi, China Recruiting

Study contacts

• Study coordinator: Shiwei Liu, Doctor
• Email: lswspring6@aliyun.com
• Phone: +86 13191072733

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of CT-based 3D printed models on endotracheal intubation success in students

  This study tests whether training with CT-based 3D printed airway models helps students perform endotracheal intubation better than traditional teaching.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shaanxi · NCT07612995

• Gene patterns that predict response to selinexor for relapsed or refractory multiple myeloma

  We will test if multigene expression patterns can predict how adults with relapsed or refractory multiple myeloma respond to selinexor-based treatment.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07514052

• Epunamin plus DECP for relapsed or refractory multiple myeloma

  This will test whether adding Epunamin to a DECP chemotherapy regimen helps people with relapsed or refractory multiple myeloma have better treatment responses.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07497165

• Integrated Chinese and Western medicine telehealth for long-term diabetes care

  This project will test an online platform that combines Traditional Chinese Medicine and Western medicine to manage adults with type 2 diabetes remotely.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07265037

• Intraosseous infusion for critically ill hematology patients

  This study will test whether intraosseous (through-the-bone) needle infusions provide fast, reliable vascular access for adults 18–65 with severe hematologic conditions in the intensive care setting.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07239375

• Stepwise antibiotic and antifungal treatment for febrile neutropenia in blood cancer patients

  This treatment plan tests whether a stepwise escalation of antibiotics and antifungals can control infection and fever in adults with hematologic malignancies who develop febrile neutropenia.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07204522

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.